SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SOUTH SAN FRANCISCO, Calif.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">July 17, 2026</span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IDYA">IDYA</a>), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society of Medical Oncology (ESMO) meeting, taking place on October 23-27 in Madrid, Spain. The presentations will feature data updates from across IDEAYA&#39;s clinical pipeline, including multiple ongoing trials of darovasertib in uveal melanoma, including the registrational Phase 2/3 OptimUM-02 trial in HLA&#x2A;A2:01-negative metastatic UM (mUM), the Phase 2 OptimUM-01 trial in HLA&#x2A;A2:01-positive mUM, and the Phase 2 OptimUM-09 trial in the neoadjuvant setting of primary uveal melanoma. IDEAYA&#39;s partner, Hengrui Pharma, will also present clinical trial results from their Phase 1 study of IDE849 (SHR-4849) being conducted in China in patients with small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs).</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1161589/IDEAYA-v2-Logo.jpg?id=OA2768336" title="" alt=""></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">&#34;We&#39;re excited to showcase the breadth of our pipeline progress at this year&#39;s ESMO Congress. Additional data from our ongoing trials in both metastatic and neoadjuvant uveal melanoma, namely OptimUM-02, OptimUM-01 and OptimUM-09, bolster our conviction in the potential of darovasertib to become an important new treatment option across the uveal melanoma patient journey. We also hope to highlight the potential best-in-class profile of IDE849, our Phase 1 DLL3 TOP1 ADC, in SCLC and NECs, where monotherapy and combination trials are ongoing and the program&#39;s first registrational trial is targeted to initiate by year-end by partner Hengrui in China and in our regions, including the US,&#34; said Dr. Darrin Beaupre, Chief Medical Officer, IDEAYA Biosciences.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">IDEAYA Presentations:</b></p><p xmlns="http://www.w3.org/1999/xhtml">2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author - Mark Shackleton, MBBS, PhD, FRACP, Department of Oncology, Alfred Hospital, and Department of Cancer Medicine, Monash University, Melbourne, Australia</i></p><p xmlns="http://www.w3.org/1999/xhtml">2104P (Poster Presentation); Darovasertib with Crizotinib vs Investigator&#39;s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma (OptimUM-02): A Subgroup Analysis. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author - Sophie Piperno-Neumann, MD, PhD, Institute Curie Research University, Paris, France</i> </p><p xmlns="http://www.w3.org/1999/xhtml">2086P (Poster Presentation); Darovasertib and Crizotinib for HLA-A&#x2A;02–Positive Metastatic Uveal Melanoma: Results from the Phase 2 OptimUM-01 Study. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author - Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, Tennessee, United States</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Hengrui Presentation:</b></p><p xmlns="http://www.w3.org/1999/xhtml">3815P (Poster Presentation); SHR-4849 (IDE849), an ADC targeting delta-like ligand 3 (DLL3), in relapsed small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs): long-term results from the Phase 1 study. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author – Haifeng Liu, PhD, Professor, Clinical Research Ward, Jilin Cancer Hospital, Changchun, China</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About IDEAYA Biosciences</b></p><p xmlns="http://www.w3.org/1999/xhtml">IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer. </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to IDEAYA&#39;s expectations, beliefs and plans regarding its clinical development programs, including the potential therapeutic benefits, clinical profile, and differentiating characteristics of darovasertib, IDE849, IDE892 and IDE397; the timing conduct and anticipated results of ongoing and planned clinical trials, including anticipated initiation of registrational trials; the potential of darovasertib to become an important new treatment option across the uveal melanoma treatment paradigm; the potential best-in-class profile of IDE849; the anticipated future growth of IDEAYA&#39;s pipeline and portfolio; the expected presentation and content of clinical data at the 2026 ESMO Congress; the activities and expected performance of IDEAYA&#39;s collaboration partners, including Hengrui Pharma; and the potential of IDEAYA&#39;s product candidates to address unmet medical needs. Such forward-looking statements are based on management&#39;s current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA&#39;s clinical programs, regulatory activities, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials; patient enrollment rates and retention; biomarker identification, patient selection and diagnostic testing; safety, tolerability, and efficacy results; regulatory interactions and decisions; the ability to translate preclinical findings into clinical benefit; manufacturing and supply risks; competition and changes in standard of care; the timing and success of commercialization efforts; the performance of IDEAYA&#39;s collaboration partners, including their ability to conduct clinical development activities and achieve anticipated development and regulatory milestones; the outcome of collaborations and licensing arrangements; IDEAYA&#39;s ability to successfully establish, protect and defend its intellectual property; and other matters that could affect the sufficiency of financial resources to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA&#39;s filings with the Securities and Exchange Commission, including IDEAYA&#39;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and current Reports on Form 8-K.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investor and Media Contact</b></p><p xmlns="http://www.w3.org/1999/xhtml">IDEAYA Biosciences<br xmlns="http://www.w3.org/1999/xhtml"></br>Joshua Bleharski, Ph.D.<br xmlns="http://www.w3.org/1999/xhtml"></br>Chief Financial Officer<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investor@ideayabio.com" target="_blank" rel="nofollow">investor@ideayabio.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=SF06795&amp;sd=2026-07-17"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-clinical-programs-302828546.html" target="_blank">https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-clinical-programs-302828546.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE IDEAYA Biosciences, Inc.</p>

IDYA

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

IDEAYA to present darovasertib and IDE849 data at ESMO 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>IDEAYA announces three ESMO abstracts for darovasertib and IDE849, with OptimUM-02/01/09 updates and Hengrui data in SCLC/NECs. The key near-term catalyst is potential registrational IDE849 trial initiation by year-end, plus broader pipeline validation in uveal melanoma. Positive data could re-rate valuation, though outcomes remain uncertain amid clinical trial risks.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>IDEAYA to present three darovasertib abstracts at ESMO 2026.</li><li>Data from OptimUM-02/01/09 in uveal melanoma highlighted.</li><li>Hengrui to present IDE849 data in SCLC/NECs.</li><li>IDEAYA targets year-end initiation of IDE849 registrational trial.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>IDEAYA Biosciences, Inc. (IDYA)</strong>: Announces ESMO abstracts; pipeline progress may serve as near-term data catalyst.</li><li><strong>Hengrui Pharma (N/A)</strong>: Partner presenting IDE849 data; registrational trial initiation by year-end in China and US possible milestone.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: reflects upcoming conference data and partner updates, potential near-term catalysts on the uveal melanoma program and IDE849.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ESMO 2026 abstracts expected Oct 23-27 in Madrid may drive idya volatility.</li><li>IDE849 registrational trial initiation targeted by year-end could lift sentiment.</li><li>Hengrui data on IDE849 may influence collaboration milestones and potential revenue.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of press release: July 17, 2026.</li><li>Company: IDEAYA Biosciences, Inc. (IDYA) on NASDAQ.</li><li>ESMO 2026 in Madrid: October 23-27, 2026.</li><li>IDEAYA presentations cover OptimUM-02, OptimUM-01, OptimUM-09; IDE849 data from Hengrui.</li><li>IDE849 is a DLL3-targeting ADC with Phase 1 data; first registrational trial planned by year-end.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish for IDYA in the near term if ESMO data support efficacy; watch through Q4 2026.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SOUTH SAN FRANCISCO, Calif.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">July 17, 2026</span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IDYA">IDYA</a>), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society of Medical Oncology (ESMO) meeting, taking place on October 23-27 in Madrid, Spain. The presentations will feature data updates from across IDEAYA&#39;s clinical pipeline, including multiple ongoing trials of darovasertib in uveal melanoma, including the registrational Phase 2/3 OptimUM-02 trial in HLA&#x2A;A2:01-negative metastatic UM (mUM), the Phase 2 OptimUM-01 trial in HLA&#x2A;A2:01-positive mUM, and the Phase 2 OptimUM-09 trial in the neoadjuvant setting of primary uveal melanoma. IDEAYA&#39;s partner, Hengrui Pharma, will also present clinical trial results from their Phase 1 study of IDE849 (SHR-4849) being conducted in China in patients with small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs).</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1161589/IDEAYA-v2-Logo.jpg?id=OA2768336" title="" alt=""></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">&#34;We&#39;re excited to showcase the breadth of our pipeline progress at this year&#39;s ESMO Congress. Additional data from our ongoing trials in both metastatic and neoadjuvant uveal melanoma, namely OptimUM-02, OptimUM-01 and OptimUM-09, bolster our conviction in the potential of darovasertib to become an important new treatment option across the uveal melanoma patient journey. We also hope to highlight the potential best-in-class profile of IDE849, our Phase 1 DLL3 TOP1 ADC, in SCLC and NECs, where monotherapy and combination trials are ongoing and the program&#39;s first registrational trial is targeted to initiate by year-end by partner Hengrui in China and in our regions, including the US,&#34; said Dr. Darrin Beaupre, Chief Medical Officer, IDEAYA Biosciences.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">IDEAYA Presentations:</b></p><p xmlns="http://www.w3.org/1999/xhtml">2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author - Mark Shackleton, MBBS, PhD, FRACP, Department of Oncology, Alfred Hospital, and Department of Cancer Medicine, Monash University, Melbourne, Australia</i></p><p xmlns="http://www.w3.org/1999/xhtml">2104P (Poster Presentation); Darovasertib with Crizotinib vs Investigator&#39;s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma (OptimUM-02): A Subgroup Analysis. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author - Sophie Piperno-Neumann, MD, PhD, Institute Curie Research University, Paris, France</i> </p><p xmlns="http://www.w3.org/1999/xhtml">2086P (Poster Presentation); Darovasertib and Crizotinib for HLA-A&#x2A;02–Positive Metastatic Uveal Melanoma: Results from the Phase 2 OptimUM-01 Study. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author - Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, Tennessee, United States</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Hengrui Presentation:</b></p><p xmlns="http://www.w3.org/1999/xhtml">3815P (Poster Presentation); SHR-4849 (IDE849), an ADC targeting delta-like ligand 3 (DLL3), in relapsed small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs): long-term results from the Phase 1 study. <i xmlns="http://www.w3.org/1999/xhtml">Presenting Author – Haifeng Liu, PhD, Professor, Clinical Research Ward, Jilin Cancer Hospital, Changchun, China</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About IDEAYA Biosciences</b></p><p xmlns="http://www.w3.org/1999/xhtml">IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer. </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to IDEAYA&#39;s expectations, beliefs and plans regarding its clinical development programs, including the potential therapeutic benefits, clinical profile, and differentiating characteristics of darovasertib, IDE849, IDE892 and IDE397; the timing conduct and anticipated results of ongoing and planned clinical trials, including anticipated initiation of registrational trials; the potential of darovasertib to become an important new treatment option across the uveal melanoma treatment paradigm; the potential best-in-class profile of IDE849; the anticipated future growth of IDEAYA&#39;s pipeline and portfolio; the expected presentation and content of clinical data at the 2026 ESMO Congress; the activities and expected performance of IDEAYA&#39;s collaboration partners, including Hengrui Pharma; and the potential of IDEAYA&#39;s product candidates to address unmet medical needs. Such forward-looking statements are based on management&#39;s current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA&#39;s clinical programs, regulatory activities, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials; patient enrollment rates and retention; biomarker identification, patient selection and diagnostic testing; safety, tolerability, and efficacy results; regulatory interactions and decisions; the ability to translate preclinical findings into clinical benefit; manufacturing and supply risks; competition and changes in standard of care; the timing and success of commercialization efforts; the performance of IDEAYA&#39;s collaboration partners, including their ability to conduct clinical development activities and achieve anticipated development and regulatory milestones; the outcome of collaborations and licensing arrangements; IDEAYA&#39;s ability to successfully establish, protect and defend its intellectual property; and other matters that could affect the sufficiency of financial resources to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA&#39;s filings with the Securities and Exchange Commission, including IDEAYA&#39;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and current Reports on Form 8-K.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investor and Media Contact</b></p><p xmlns="http://www.w3.org/1999/xhtml">IDEAYA Biosciences<br xmlns="http://www.w3.org/1999/xhtml"></br>Joshua Bleharski, Ph.D.<br xmlns="http://www.w3.org/1999/xhtml"></br>Chief Financial Officer<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investor@ideayabio.com" target="_blank" rel="nofollow">investor@ideayabio.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=SF06795&amp;sd=2026-07-17"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-clinical-programs-302828546.html" target="_blank">https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-clinical-programs-302828546.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE IDEAYA Biosciences, Inc.</p>

IDEAYA announces three ESMO abstracts for darovasertib and IDE849, with OptimUM-02/01/09 updates and Hengrui data in SCLC/NECs. The key near-term catalyst is potential registrational IDE849 trial initiation by year-end, plus broader pipeline validation in uveal melanoma. Positive data could re-rate valuation, though outcomes remain uncertain amid clinical trial risks.

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News